HC Wainwright Has Strong Outlook for PolyPid FY2024 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Analysts at HC Wainwright raised their FY2024 EPS estimates for PolyPid in a research report issued on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($4.56) per share for the year, up from their previous forecast of ($4.83). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.79) EPS.

Separately, Craig Hallum assumed coverage on PolyPid in a research report on Monday, November 4th. They set a “buy” rating and a $10.00 target price on the stock.

PolyPid Trading Down 3.5 %

NASDAQ PYPD opened at $3.04 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $14.58 million, a P/E ratio of -0.39 and a beta of 1.33. PolyPid has a 52-week low of $2.37 and a 52-week high of $9.20. The firm has a 50-day moving average price of $3.23 and a 200 day moving average price of $3.49.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC purchased a new stake in PolyPid Ltd. (NASDAQ:PYPD) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid as of its most recent SEC filing. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.